Abstract
In Mexico, endometrial cancer ranks fifth in incidence and is the second cause of gynecological cancer after cervical cancer. The main risk factor for endometrial cancer is obesity and other conditions related to metabolic syndrome. The symptom that indicates the start of the approach is abnormal uterine bleeding, especially in postmenopausal patients. The standard of initial treatment for apparently localized endometrial cancer is hysterectomy. Lymph node evaluation provides relevant information on the prognosis and the need for adjuvant therapy. Various clinical and histological parameters have been associated with the survival of these patients. Additionally, data from the Cancer Genome Atlas project has increased our understanding of endometrial cancer's biological and prognostic heterogeneity. Several studies have evaluated the role of different adjuvant strategies, such as brachytherapy, radiotherapy, and chemotherapy. In advanced diseases, standard treatment consists of systemic therapy and other options include chemotherapy, hormone therapy, and immunotherapy. Surgery and radiation therapy can sometimes improve outcomes for patients with advanced disease. These guidelines aim to share with the oncology community the diagnostic and treatment strategies used at the National Cancer Institute to diagnose and treat endometrial cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
